OAM
CPRX

Oberweis Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Oberweis Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.23M Sell
293,670
-486,900
-62% -$14.4M 0.19% 135
2026
Q1 		$19.3M Buy
780,570
+193,600
+33% +$4.61M 0.57% 65
2025
Q4 		$13.7M Buy
586,970
+58,410
+11% +$1.3M 0.5% 79
2025
Q3 		$10.4M Buy
528,560
+60,360
+13% +$1.24M 0.4% 95
2025
Q2 		$10.2M Buy
468,200
+600
+0.1% +$14.2K 0.44% 83
2025
Q1 		$11.3M Buy
467,600
+500
+0.1% +$11.3K 0.57% 65
2024
Q4 		$9.75M Buy
467,100
+8,700
+2% +$187K 0.46% 82
2024
Q3 		$9.11M Hold
458,400
– – 0.47% 86
2024
Q2 		$7.1M Hold
458,400
– – 0.44% 88
2024
Q1 		$7.31M Buy
458,400
+109,800
+31% +$1.65M 0.53% 74
2023
Q4 		$5.86M Buy
348,600
+55,000
+19% +$752K 0.55% 68
2023
Q3 		$3.43M Buy
293,600
+110,200
+60% +$1.47M 0.36% 108
2023
Q2 		$2.46M Buy
183,400
+36,000
+24% +$518K 0.3% 120
2023
Q1 		$2.44M Buy
147,400
+50,800
+53% +$838K 0.38% 88
2022
Q4 		$1.8M Buy
+96,600
New +$1.49M 0.38% 81

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Oberweis Asset Management's CPRX Position: Q2 2026 in Review

Oberweis Asset Management reduced its Catalyst Pharmaceutical (CPRX) stake by 62% in Q2 2026, selling an estimated $14.4M and leaving 293,670 shares worth $9.23M. The position accounts for 0.19% of the portfolio, ranked #135.

Oberweis Asset Management first reported a position in CPRX in Q4 2022 and has held it in 15 quarters since. The position peaked at $19.3M in Q1 2026. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Oberweis Asset Management held 293,670 shares of Catalyst Pharmaceutical worth $9.23M as of Q2 2026.
  • Oberweis Asset Management sold 486,900 Catalyst Pharmaceutical shares in Q2 2026, an estimated $14.4M.
  • Catalyst Pharmaceutical made up 0.19% of Oberweis Asset Management's portfolio in Q2 2026, its #135 holding.
  • Oberweis Asset Management first reported a position in Catalyst Pharmaceutical in Q4 2022 and has held it in 15 quarters since.
  • Oberweis Asset Management's Catalyst Pharmaceutical position peaked at $19.3M in Q1 2026.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Oberweis Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.